Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Novel, orally bioavailable HSP 90 inhibitor developed by Taiho for cancer

Nov. 29, 2012

TAS-114 demonstrates promising antitumor activity in combination with other oncolytic agents

Nov. 29, 2012

Novel shRNA molecule demonstrates potential efficacy for patients with mesothelioma

Nov. 29, 2012

Phase II study of ProHema for hematologic malignancies begins

Nov. 28, 2012

Amgen synthesizes novel protein kinase inhibitors

Nov. 28, 2012

Ruga presents next-generation B-raf V600E inhibitors

Nov. 28, 2012

MMRF partners with the Department of Veterans Affairs

Nov. 28, 2012

EMA accepts for review MAAs for vintafolide and etarfolatide

Nov. 28, 2012

CAP-7.1 evaluated in patients with solid tumors

Nov. 28, 2012

New CDK8 inhibitors designed for the treatment of colorectal cancer

Nov. 27, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....